Benitec Biopharma Inc (BNTC)
$11.1
Live
Performance
- $10.94$11.34$11.10
1.45%
Downside
Day's Volatility :3.54%
Upside
2.12%
- $2.69$12.89$11.10
75.77%
Downside
52 Weeks Volatility :79.13%
Upside
13.89%
Returns
| Period | Benitec Biopharma Inc | Index (Russel 2000) |
|---|---|---|
3 Months | 28.12% | 0.0% |
6 Months | 70.83% | 0.0% |
1 Year | 257.08% | 0.0% |
3 Years | -81.85% | -23.0% |
Highlights
Market Capitalization | 229.6M |
Book Value | $4.68 |
Earnings Per Share (EPS) | -5.51 |
PEG Ratio | 0.0 |
Wall Street Target Price | 24.0 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -49.6% |
Return On Equity TTM | -91.68% |
Revenue TTM | 7.0K |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 12.5% |
Gross Profit TTM | 75.0K |
EBITDA | -22.4M |
Diluted Eps TTM | -5.51 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -5.22 |
EPS Estimate Next Year | -1.81 |
EPS Estimate Current Quarter | -0.49 |
EPS Estimate Next Quarter | -0.42 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 116.22%
Technicals Summary
Sell
Neutral
Buy
Benitec Biopharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Benitec Biopharma Inc | 29.28% | 70.83% | 257.08% | -81.85% | -92.9% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Benitec Biopharma Inc | NA | NA | 0.0 | -5.22 | -0.92 | -0.5 | NA | 4.68 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Benitec Biopharma Inc | Buy | $229.6M | -92.9% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Benitec Biopharma Inc
Decreasing Revenue
Revenue is down for the last 3 quarters, 54.0K → 6.0K (in $), with an average decrease of 50.7% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -4.27M → -4.72M (in $), with an average decrease of 10.3% per quarter
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 126.6%
Institutional Holdings
Suvretta Capital Management, LLC
16.77%HHG PLC
8.93%Nantahala Capital Management, LLC
8.34%Adage Capital Partners Gp LLC
8.34%Franklin Resources Inc
7.90%Schonfeld Strategic Advisors LLC
2.58%
Company Information
benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
Organization | Benitec Biopharma Inc |
Employees | 16 |
CEO | Dr. Jerel A. Banks M.D., Ph.D. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$11.10
-3.31%
Invesco Bulletshares 2025 Hi
$11.10
-3.31%
Schwab International Dividend Equity Etf
$11.10
-3.31%
Blockchain Coinvestors Acquisition Corp.
$11.10
-3.31%
Allgiant Travel Company
$11.10
-3.31%
Rogers Corp
$11.10
-3.31%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$11.10
-3.31%
Iheartmedia
$11.10
-3.31%
Lightpath Technologies Inc
$11.10
-3.31%